Current options and future directions in the systemic treatment of metastatic melanoma

Journal of Community and Supportive Oncology

Volumn 12, Issue 1, 2014, Pages 20-26

  Schindler, Katja ^a   Postow, Michael A ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKYLATING AGENT; ATEZOLIZUMAB; B RAF KINASE INHIBITOR; BLOCKING ANTIBODY; CARBOPLATIN; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; DABRAFENIB; DACARBAZINE; DURVALUMAB; ENCORAFENIB; GLYCOPROTEIN 100 PEPTIDE VACCINE; GLYCOPROTEIN GP 100; IPILIMUMAB; MITOGEN ACTIVATED PROTEIN KINASE KINASE INHIBITOR; MONOCLONAL ANTIBODY; NITROSOUREA; NIVOLUMAB; PACLITAXEL; PEMBROLIZUMAB; PEPTIDE VACCINE; PLACEBO; PLATINUM DERIVATIVE; PROGRAMMED DEATH 1 RECEPTOR; RECOMBINANT INTERLEUKIN 2; TEMOZOLOMIDE; TICILIMUMAB; TRAMETINIB; UNCLASSIFIED DRUG; VEMURAFENIB; VINBLASTINE;

ACUTE TOXICITY; BONE MARROW SUPPRESSION; CANCER CHEMOTHERAPY; CAPILLARY LEAK SYNDROME; CARDIOVASCULAR DISEASE; COLITIS; FATIGUE; HEPATITIS; HUMAN; HYPOPHYSITIS; IMMUNOTHERAPY; METASTATIC MELANOMA; MUTATION; NAUSEA; OUTCOME ASSESSMENT; REVIEW; SEIZURE; SYSTEMIC THERAPY; THYROIDITIS; TUMOR IMMUNITY; TUMOR REGRESSION; VITILIGO;

EID: 84970924679     PISSN: 23307749     EISSN: None     Source Type: Journal    
DOI: 10.12788/jcso.0005     Document Type: Review

References (60)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012; 62: 10-29
2. Garbe C, Peris K, Hauschild A., et al. Diagnosis and treatment of melanoma. European consensus-based interdisciplinary guideline - Update 2012. Eur J Cancer. 2012; 48: 2375-2390
3. Coit DG, Andtbacka R, Bichakjian CK., et al. Melanoma. J Natl Compr Ca Netw. 2009; 7: 250-275
4. Molife R, Hancock BW. Adjuvant therapy of malignant melanoma. Crit Rev Oncol Hematol. 2002; 44: 81-102
5. Wheatley K, Ives N, Hancock B, Gore M, Eggermont A, Suciu S. Does adjuvant interferon-Alpha for high-risk melanoma provide a worthwhile beneft? A meta-Analysis of the randomised trials. Cancer Treat Rev. 2003; 29: 241-252
6. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-Analysis. J Natl Cancer Inst. 2010; 102: 493-501
7. Balch CM, Gershenwald JE, Soong SJ., et al. Final version of 2009 AJCC melanoma staging and classifcation. J Clin Oncol. 2009; 27: 6199-6206
8. Luke JJ, Rubinstein LV, Smith GL, Ivy SP, Harris PJ. Similar efcacy for phase I trials in comparison with DTIC for advanced malignant melanoma: an analysis of melanoma outcomes in CTEP-sponsored phase I trials 1995-2011. Melanoma Res. 2013; 23: 152-158
9. Middleton MR, Grob JJ, Aaronson N., et al. Randomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanoma. J Clin Oncol. 2000; 18: 158-166
10. Teimouri F, Nikfar S, Abdollahi M. Efcacy and side efects of dacarbazine in comparison with temozolomide in the treatment of malignant melanoma: a meta-Analysis consisting of 1314 patients. Melanoma Res. 2013; 23: 381-389
11. Chapman PB, Einhorn LH, Meyers ML., et al. Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol. 1999; 17: 2745-2751
12. Legha SS, Ring S, Papadopoulos N, Plager C, Chawla S, Benjamin R. A prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanoma. Cancer. 1989; 64: 2024-2029
13. Rao RD, Holtan SG, Ingle JN., et al. Combination of paclitaxel and carboplatin as second-line therapy for patients with metastatic melanoma. Cancer. 2006; 106: 375-382
14. Atkins MB, Kunkel L, Sznol M, Rosenberg SA. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival update. Cancer J Sci Am. 2000; 6(suppl 1): S11-S4
15. Atkins MB, Lotze MT, Dutcher JP., et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol. 1999; 17: 2105-2116
16. Schwartzentruber DJ, Lawson DH, Richards JM., et al. gp100 peptide vaccine and interleukin-2 in patients with advanced melanoma. N Engl J Med. 2011; 364: 2119-2127
17. Johannsen M, Spitaleri G, Curigliano G., et al. Te tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer. 2010; 46: 2926-2935
18. Eigentler TK, Weide B, de Braud F., et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res. 2011; 17: 7732-7742
19. Hodi FS, O'Day SJ, McDermott DF., et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010; 363: 711-723
20. Robert C, Tomas L, Bondarenko I., et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011; 364: 2517-2526
21. Ribas A, Keford R, Marshall MA., et al. Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. J Clin Oncol. 2013; 31: 616-622
22. Wolchok JD, Weber JS, Maio M., et al. Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials. Ann Oncol. 2013; 24: 2174-2180
23. Weber JS, Kahler KC, Hauschild A. Management of immunerelated adverse events and kinetics of response with ipilimumab. J Clin Oncol. 2012; 30: 2691-2697
24. Di Giacomo AM, Biagioli M, Maio M. Te emerging toxicity profles of anti-CTLA-4 antibodies across clinical indications. Semin Oncol. 2010; 37: 499-507
25. Harmankaya K, Erasim C, Koelblinger C., et al. Continuous systemic corticosteroids do not afect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy. Med Oncol. 2011; 28: 1140-1144
26. Wolchok JD, Hoos A, O'Day S., et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009; 15: 7412-7420
27. Zou W, Chen L. Inhibitory B7-family molecules in the tumour microenvironment. Nat Rev Immunol. 2008; 8: 467-477
28. Keir ME, Liang SC, Guleria I., et al. Tissue expression of PD-L1 mediates peripheral T cell tolerance. J Exp Med. 2006; 203: 883-895
29. Topalian SL, Hodi FS, Brahmer JR., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med. 2012; 366: 2443-2454
30. Sznol M, Kluger HM, Hodi FS. Survival and long-term followup of safety and response in patients (pts) with advanced melanoma (MEL) in a phase I trial of nivolumab (anti-PD-1; BMS-936558; ONO-4538) [ASCO abstract CRA9006]. J Clin Oncol. 2013; 319(suppl
31. Wolchok JD, Kluger H, Callahan MK., et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013; 369: 122-133
32. Hamid O, Robert C, Daud A., et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369: 134-144
33. Brahmer JR, Tykodi SS, Chow LQ., et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366: 2455-2465
34. McCubrey JA, Steelman LS, Chappell WH., et al. Roles of the Raf/ MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta. 2007; 1773: 1263-1284
35. Curtin JA, Busam K, Pinkel D, Bastian BC. Somatic activation of KIT in distinct subtypes of melanoma. J Clin Oncol. 2006; 24: 4340-4346
36. Davies H, Bignell GR, Cox C., et al. Mutations of the BRAF gene in human cancer. Nature. 2002; 417: 949-954
37. Long GV, Menzies AM, Nagrial AM., et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol. 2011; 29: 1239-1246
38. Bollag G, Hirth P, Tsai J., et al. Clinical efcacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma. Nature. 2010; 467: 596-599
39. Flaherty KT, Puzanov I, Kim KB., et al. Inhibition of mutated, activated BRAF in metastatic melanoma. New J Engl Med. 2010; 363: 809-819
40. Chapman PB, Hauschild A, Robert C., et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. New J Engl Med. 2011; 364: 2507-2516
41. Chapman PB, Hauschild A, Robert C., et al. Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with BRAF(V600E)-mutated melanoma [ASCO abstract 8502]. J Clin Oncol. 2012; 30(suppl
42. Lacouture ME, O'Reilly K, Rosen N, Solit DB. Induction of cutaneous squamous cell carcinomas by RAF inhibitors: cause for concern? J Clin Oncol. 2012; 30: 329-330
43. Su F, Viros A, Milagre C., et al. RAS mutations in cutaneous squamous- cell carcinomas in patients treated with BRAF inhibitors. New Engl J Med. 2012; 366: 207-215
44. Callahan MK, Rampal R, Harding JJ., et al. Progression of RASmutant leukemia during RAF inhibitor treatment. New Engl J Med. 2012; 367: 2316-2321
45. Zimmer L, Hillen U, Livingstone E., et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol. 2012; 30: 2375-2383
46. Hauschild A, Grob JJ, Demidov LV., et al. Dabrafenib in BRAFmutated metastatic melanoma: a multicentre, open-label phase 3 randomised clinical trial. Lancet 2012; 380: 358-65
47. Long GV, Trefzer U, Davies MA., et al. Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012; 13: 1087-1095
48. Flaherty KT, Robert C, Hersey P., et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. New Engl J Med. 2012; 367: 107-14
49. Kirkwood JM, Bastholt L, Robert C., et al. Phase II, open-label, randomized trial of the MEK1/2 inhibitor selumetinib as monotherapy versus temozolomide in patients with advanced melanoma. Clin Cancer Res. 2012; 18: 555-567
50. Poulikakos PI, Persaud Y, Janakiraman M., et al. RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E). Nature. 2011; 480: 387-390
51. Nazarian R, Shi H, Wang Q., et al. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation. Nature. 2010; 468: 973-977
52. Flaherty KT, Infante JR, Daud A., et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. New Engl J Med. 2012; 367: 1694-1703
53. Ugurel S, Hildenbrand R, Zimpfer A., et al. Lack of clinical efcacy of imatinib in metastatic melanoma. Br J Cancer. 2005; 92: 1398-1405
54. Wyman K, Atkins MB, Prieto V., et al. Multicenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: signifcant toxicity with no clinical efcacy. Cancer. 2006; 106: 2005-2011
55. Kim KB, Eton O, Davis DW., et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer. 2008; 99: 734-740
56. Carvajal RD, Antonescu CR, Wolchok JD., et al. KIT as a therapeutic target in metastatic melanoma. JAMA. 2011; 305: 2327-2334
57. Hodi FS, Corless CL, Giobbie-Hurder A., et al. Imatinib for melanomas harboring mutationally activated or amplifed KIT arising on mucosal, acral, and chronically sun-damaged skin. J Clin Oncol. 2013; 31: 3182-3190
58. Guo J, Si L, Kong Y., et al. Phase II, open-label, single-Arm trial of imatinib mesylate in patients with metastatic melanoma harboring c-Kit mutation or amplifcation. J Clin Oncol. 2011; 29: 2904-290958
59. Ribas A, Hodi FS, Callahan M, Konto C, Wolchok J. Hepatotoxicity with combination of vemurafenib and ipilimumab. New Engl J Med. 2013; 368: 1365-1366
60. Ribas A, Hodi FS, Callahan M., et al. Hepatotoxicity with combination of vemurafenib and ipilimumab. N Engl J Med 2013; 368: 1365-6.